Category: News

INHSU 2019: Wholistic hepatitis C care, and the importance of care providers

Hundreds of clinicians, researchers and people with lived experience gathered in Montreal in September 2019 to highlight promising work in hepatitis C research and practice. The 8th International Conference on Hepatitis Care in Substance Users (INHSU 2019) showcased innovative models of care that support the delivery of hepatitis C treatment.

Read more

Reaching the first 90: how HIV self-testing can help us end the HIV epidemic

Canada has signed on to the global 90-90-90 targets to end the HIV epidemic by 2030. The aim of these targets is to diagnose at least 90% of all people living with HIV, provide treatment for 90% of those diagnosed, and for 90% of people on treatment to have an undetectable viral load by 2020. However, Canada is falling short on the first 90, lagging behind other similar countries, such as the United Kingdom and Australia.

Read more

Can’t Pass It On: Rainer and Eka’s story

CATIE recently launched its Can’t Pass It On campaign to increase awareness that people living with HIV on effective treatment can’t pass it on to a partner. The series features real serodifferent couples with one HIV-positive and one HIV-negative partner. CATIE sat down with one of these couples, Rainer Oktovianus and Eka Nasution, to learn more about their story and why they chose to participate in the campaign. 

Read more

An “HIV status neutral” paradigm shift

HIV is not what it used to be. Many people with HIV describe it as a chronic condition and a manageable part of their life. HIV prevention is not what it used to be, either. The simultaneous rise of “undetectable equals untransmittable” (U=U) and pre-exposure prophylaxis (PrEP) caused a radical change in the way we talk about HIV transmission and prevention.

Read more

Meeting people where they are is about much more than location: Delivering hepatitis C care and treatment to people who use drugs

Poverty, stigma and criminalization are chronic problems among people who use and inject drugs. But hepatitis C virus (HCV) is no longer such a problem, since it is usually cured by eight to 12 weeks of oral, direct-acting antivirals (DAAs). Delivering DAAs to people who use and inject drugs in the context of the chronic problems facing them is an opportunity to recognize and support the contribution of people with lived experience, and to build and strengthen systems and programs.

Read more